Immunology Leader Vincenzo Cerundolo Dies

The Oxford researcher’s work on lipid and peptide antigens revealed key mechanisms in inflammation, immunotherapy, and vaccination, which are being pursued in clinical trial treatments.

Written byAshley Yeager
| 2 min read

Register for free to listen to this article
Listen with Speechify
0:00
2:00
Share

ABOVE: MRC Weatherall Institute of Molecular Medicine

Vincenzo Cerundolo, an immunologist at the University of Oxford, died last week (January 7) of non-smoking-related lung cancer. He was 60.

Cerundolo “is a scientific star for his discoveries,” Netherland Cancer Institute oncologist John Haanen and University of Lausanne cancer researcher Solange Peters wrote last year on a GoFundMe page to help raise funds for Cerundolo’s treatment. “Apart from his great scientific work (he is still publishing!), [he] is a fantastic and warm human being, and a very dear friend.”

Cerundolo was born in Lecce, Italy, on December 20, 1959 and later studied medicine at the University of Padua, where he stayed, earning his PhD in immunology in 1987. He then moved to the Medical Research Council (MRC) Weatherall Institute of Molecular Medicine at the University of Oxford for a postdoc with Alain Townsend, where he investigated the way T cells recognize and ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to more than 35 years of archives, as well as TS Digest, digital editions of The Scientist, feature stories, and much more!
Already a member? Login Here

Related Topics

Meet the Author

  • Ashley started at The Scientist in 2018. Before joining the staff, she worked as a freelance editor and writer, a writer at the Simons Foundation, and a web producer at Science News, among other positions. She holds a bachelor’s degree in journalism from the University of Tennessee, Knoxville, and a master’s degree in science writing from MIT. Ashley edits the Scientist to Watch and Profile sections of the magazine and writes news, features, and other stories for both online and print.

    View Full Profile
Share
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies